Sign In
Buy AMGN
$338.22
+9.96 (+3.03%)
At Close: Jun 03, 2026
Amgen's Q1 Earnings Top Estimates, 16 Drugs Deliver Double-Digit Gains
10:16am, Friday, 01'st May 2026
AMGN beats Q1 estimates as 16 drugs post double-digit growth, offsetting biosimilar erosion and weaker legacy products while lifting 2026 outlook.
Amgen Inc. (AMGN) Q1 2026 Earnings Call Transcript
04:21am, Friday, 01'st May 2026
Amgen Inc. (AMGN) Q1 2026 Earnings Call Transcript
Amgen Inc (AMGN) Q1 2026 Earnings Call Highlights: Strong Product Sales Growth Amidst Competitive Challenges
02:17am, Friday, 01'st May 2026
Revenue: Total revenues expected in the range of $37.1 billion to $38.5 billion for 2026.Product Sales Growth: 4% growth in product sales in Q1 2026.Key Growth
Amgen (AMGN) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates
07:01pm, Thursday, 30'th Apr 2026
While the top- and bottom-line numbers for Amgen (AMGN) give a sense of how the business performed in the quarter ended March 2026, it could be worth looking at how some of its key metrics compare to
Amgen (AMGN) Q1 Earnings and Revenues Beat Estimates
06:15pm, Thursday, 30'th Apr 2026
Amgen (AMGN) came out with quarterly earnings of $5.15 per share, beating the Zacks Consensus Estimate of $4.73 per share. This compares to earnings of $4.9 per share a year ago.
Amgen Posts Higher First-Quarter Profit, Revenue
04:19pm, Thursday, 30'th Apr 2026
The biotechnology company reported a profit of $1.82 billion, driven by a 4% rise in product sales.
Amgen sales rise 4% in first quarter, submits label update to FDA on autoimmune drug
04:06pm, Thursday, 30'th Apr 2026
Amgen on Thursday reported first-quarter product sales rose 4%, helped by demand for cholesterol and rare disease medicines, and said it was moving forward with a broad development program for e
AMGEN REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS
04:01pm, Thursday, 30'th Apr 2026
THOUSAND OAKS, Calif., April 30, 2026 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced financial results for the first quarter of 2026.
Amgen to Report Q1 Earnings: Can It Keep the Beat Streak Alive?
01:15pm, Tuesday, 28'th Apr 2026
Amgen heads into Q1 earnings with growth from key drugs offset by pricing pressure, patent losses, and biosimilar competition.
Is iShares Biotechnology ETF (IBB) a Strong ETF Right Now?
07:20am, Tuesday, 28'th Apr 2026
The iShares Biotechnology ETF (IBB) was launched on 02/05/2001, and is a smart beta exchange traded fund designed to offer broad exposure to the Health Care ETFs category of the market.
FDA proposes to withdraw Amgen's rare autoimmune disease drug
09:04pm, Monday, 27'th Apr 2026
The U.S. Food and Drug Administration's Center for Drug Evaluation and Research on Monday proposed withdrawing approval of Amgen's drug for a group of rare autoimmune diseases, citing a
Pharma bets a little-known cholesterol will underpin its next blockbuster heart drugs
12:55pm, Monday, 27'th Apr 2026
Novartis, Amgen and Eli Lilly are among the pharmaceutical companies developing drugs to lower levels of a particularly bad form of cholesterol called Lp(a) and potentially prevent heart attacks. Lp(a
Exploring Analyst Estimates for Amgen (AMGN) Q1 Earnings, Beyond Revenue and EPS
10:16am, Monday, 27'th Apr 2026
Evaluate the expected performance of Amgen (AMGN) for the quarter ended March 2026, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for
TOMI Environmental Solutions, Inc. Sees Strong Interest In Its Solutions at INTERPHEX 2026
08:30am, Monday, 27'th Apr 2026
Company Showcases SteraMist iHP Automation to Industry Giants Including Amgen, Merck, and Moderna; Finalizes Custom Engineering Contract for Proprietary Healthcare System Company Showcases SteraMist i
AMGN DCF Analysis: Intrinsic Value $289 vs Price $345
07:26am, Monday, 27'th Apr 2026
On April 27, 2026, we present a detailed DCF analysis for Amgen Inc (AMGN), a company that has shown a price performance of +27.0% over the past year, despite a
